Skip to main content
SpringerLink
Log in

Certolizumab Pegol: A Review of Its Use in Patients with Axial Spondyloarthritis or Psoriatic Arthritis

  • Adis Drug Evaluation
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Certolizumab pegol (Cimzia®) is a polyethylene glycolylated antigen-binding fragment of a recombinant human monoclonal antibody that binds to and selectively neutralizes tumour necrosis factor (TNF) α. In the EU, subcutaneous certolizumab pegol is indicated for the treatment of adults with severe active axial spondyloarthritis (axSpA), comprising ankylosing spondylitis (AS) and non-radiographic axSpA (nr-axSpA), and for adults with active psoriatic arthritis (PsA). In the USA it is indicated for the treatment of adults with active AS or active PsA. This article reviews the efficacy and tolerability of certolizumab pegol in these patients and briefly summarizes its pharmacology. In two ongoing, well-designed studies, data at 12 and 24 weeks showed that treatment with certolizumab pegol (200 mg every 2 weeks or 400 mg every 4 weeks) was effective in improving the clinical signs and symptoms of disease, health-related quality of life and productivity in patients with axSpA (the RAPID-axSpA study) or PsA (the RAPID-PsA study), with the improvements maintained during longer-term (48 weeks) treatment. Within the axSpA population, clinical benefits with certolizumab pegol were seen both in patients with AS and in those with nr-axSpA. In addition, 12 weeks’ treatment with certolizumab pegol reduced inflammation in the sacroiliac joints and spine in patients with axSpA and 24 weeks’ treatment with the agent slowed radiographic disease progression in patients with PsA. Certolizumab pegol was generally well tolerated in these studies, with a tolerability profile consistent with that seen in previous clinical trials in other indications. Although additional long-term and comparative data are needed to position certolizumab pegol with respect to other TNFα antagonists, current evidence indicates that certolizumab pegol is an effective option for the treatment of axSpA (including AS and nr-axSpA) and PsA.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. van Tubergen A, Weber U. Diagnosis and classification in spondyloarthritis: identifying a chameleon. Nat Rev Rheumatol. 2012;8(5):253–61.

    Article  PubMed  Google Scholar 

  2. van der Horst-Bruinsma IE. Treatment of non-radiographic axial spondyloarthritis: it is only the beginning. Ann Rheum Dis. 2013;72(6):789–90.

    Article  PubMed  Google Scholar 

  3. Rudwaleit M, van der Heijde D, Landewe R, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis. 2009;68(6):777–83.

    Article  CAS  PubMed  Google Scholar 

  4. Paul S, Keat A. Assessment of patients with spondyloarthropathies for treatment with tumour necrosis factor alpha blockade. Rheumatology. 2005;44(1):17–23.

    Article  CAS  PubMed  Google Scholar 

  5. Canete JD, Llena J, Collado A, et al. Comparative cytokine gene expression in synovial tissue of early rheumatoid arthritis and seronegative spondyloarthropathies. Br J Rheumatol. 1997;36(1):38–42.

    Article  CAS  PubMed  Google Scholar 

  6. Danning CL, Illei GG, Hitchon C, et al. Macrophage-derived cytokine and nuclear factor kappaB p65 expression in synovial membrane and skin of patients with psoriatic arthritis. Arthritis Rheum. 2000;43(6):1244–56.

    Article  CAS  PubMed  Google Scholar 

  7. Gratacos J, Collado A, Filella X, et al. Serum cytokines (IL-6, TNF-alpha, IL-1 beta and IFN-gamma) in ankylosing spondylitis: a close correlation between serum IL-6 and disease activity and severity. Br J Rheumatol. 1994;33(10):927–31.

    Article  CAS  PubMed  Google Scholar 

  8. Deeks ED. Certolizumab pegol: a review of its use in the management of rheumatoid arthritis. Drugs. 2013;73(1):75–97.

    Article  CAS  PubMed  Google Scholar 

  9. Duggan ST, Keam SJ. Certolizumab pegol: in rheumatoid arthritis. BioDrugs. 2009;23(6):407–17.

    Article  CAS  PubMed  Google Scholar 

  10. European Medicines Agency. Cimzia (certolizumab pegol): summary of product characteristics. 2014. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001037/WC500069763.pdf. Accessed 8 May 2014.

  11. UCB Inc. Cimzia (certolizumab pegol): US prescribing information. 2013. http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125160s215lbl.pdf. Accessed 8 MAy 2014.

  12. European Medicines Agency. Assessment report for cimzia (EMEA/H/C/001037). 2009. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/001037/WC500069735.pdf. Accessed 21 Jan 2014.

  13. Landewe R, Braun J, Deodhar A, et al. Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled phase 3 study. Ann Rheum Dis. 2014;73(1):39–47.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  14. Mease PJ, Fleischmann R, Deodhar AA, et al. Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a phase 3 double-blind randomised placebo-controlled study (RAPID-PsA). Ann Rheum Dis. 2014;73(1):48–55.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  15. European Medicines Agency. Cimzia: assessment report (EMEA/H/C/001037/II/29). 2013. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/001037/WC500153994.pdf. Accessed 18 Dec 2013.

  16. European Medicines Agency. Cimzia: assessment report (EMEA/H/C/001037/II/27). 2013. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/001037/WC500159001.pdf. Accessed 8 May 2014.

  17. Sieper J, Kivitz AJ, Van Tubergen AM, et al. Rapid improvements in patient reported outcomes with certolizumab pegol in patients with axial spondyloarthritis, including ankylosing spondyltitis and non-radiographic axial spondyloarthritis: 24 week results of a phase 3 double blind randomized placebo-controlled study [abstract no. 558]. Arthritis Rheum. 2012;64(Suppl 10):S243.

    Google Scholar 

  18. Landewe R, Rudwaleit M, Van Der Heijde D, et al. Effect of certolizumab pegol over 48 weeks in patients with axial spondyloarthritis, including ankylosing spondylitis and non-radiographic axial spondyloarthritis [abstract no. 1799]. Arthritis Rheum. 2013;65(10 Suppl):S767.

    Google Scholar 

  19. van Der Heijde D, Maksymowych WP, Landewe RBM, et al. Effect of certolizumab pegol on inflammation of spine and sacroiliac joints in patients with axial spondyloarthritis: 12 week magnetic resonance imaging results of a phase 3 double blind randomized placebo-controlled study [abstract no. 1705]. Arthritis Rheum. 2012;64(Suppl 10):S730.

    Google Scholar 

  20. van Der Heijde D, Braun J, Rudwaleit M, et al. Increased participation in daily activities after 24 weeks of certolizumab pegol treatment of axial spondyloarthritis patients, including patients with ankylosing spondylitis: results of a phase 3 double-blind randomized placebo-controlled study [abstract no. 1372]. Arthritis Rheum. 2012;64(Suppl 10):S592.

    Google Scholar 

  21. van Der Heijde D, Braun J, Rudwaleit M, et al. Reduction of disease burden on workplace and household productivity in axial spondyloarthritis, including ankylosing spondylitis and non-radiographic axial spondyloarthritis, over 48 weeks of treatment with certolizumab pegol [abstract no. 1520]. Arthritis Rheum. 2013;65(Suppl 10):S644.

    Google Scholar 

  22. Mease P, Fleischmann R, Wollenhaupt J, et al. Effect of certolizumab pegol over 48 weeks on signs and symptoms in patients with psoriatic arthritis with and without prior tumor necrosis factor inhibitor [abstract no. 312]. Arthritis Rheum. 2013;65(Suppl 10):S132.

    Google Scholar 

  23. Gladman D, Fleischmann R, Coteur G, et al. Long-term maintenance of improvements in multiple facets of psoriatic arthritis with certolizumab pegol: 48-week patient-reported outcome results of the RAPID-PSA study [abstract no. PMS81]. Value Health. 2013;16(7):A569.

    Article  Google Scholar 

  24. Kavanaugh A, Gladman D, van der Heijde D, et al. Improvements in productivity at paid work and within household, and increased participation in daily activities after 24 weeks of certolizumab pegol treatment of patients with psoriatic arthritis: results of a phase III double-blind randomized placebo-controlled study [abstract no. 286]. Rheumatology. 2013;52(Suppl 1):i163–4.

    Google Scholar 

  25. Kavanaugh A, Gladman D, Van Der Heijde D, et al. Reduction of disease burden on workplace and household productivity in psoriatic arthritis over 48 weeks of treatment with certolizumab pegol [abstract no. 326]. Arthritis Rheum. 2013;65(Suppl 10):S140.

    Google Scholar 

  26. Landewe RBM, Rudwaleit M, Van Der Heijde D, et al. Effect of certolizumab pegol on signs and symptoms of ankylosing spondyltitis and non-radiographic axial spondyloarthritis: 24 week results of a double blind randomized placebo-controlled phase 3 axial spondyloarthritis study [abstract no. 777]. Arthritis Rheum. 2012;64(10 Suppl):S336–S7.

  27. Mease PJ, Fleischmann R, Wollenhaupt J, et al. Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis from the RAPID-PsA study: impact of baseline skin involvement and prior anti-TNF therapy [abstract no. SAT0298]. Ann Rheum Dis. 2013;72(Suppl 3):684.

    Google Scholar 

  28. van der Heijde D, Fleischmann R, Wollenhaupt J, et al. Effect of different imputation approaches on the evaluation of radiographic progression in patients with psoriatic arthritis: results of the RAPID-PsA 24-week phase III double-blind randomised placebo-controlled study of certolizumab pegol. Ann Rheum Dis. 2013. doi:10.1136/annrheumdis-2013-203697.

    Google Scholar 

  29. Kavanaugh A, van der Heijde D, McInnes IB, et al. Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial. Arthritis Rheum. 2012;64(8):2504–17.

    Article  CAS  PubMed  Google Scholar 

  30. Gladman D, Fleischmann R, Coteur G, et al. Effect of certolizumab pegol on multiple facets of psoriatic arthritis as reported by patients: 24-week patient-reported outcome results of the RAPID-PsA study. Arthritis Care Res. 2013. doi:10.1002/acr.22256.

  31. Bykerk VP, Cush J, Winthrop K, et al. Update on the safety profile of certolizumab pegol in rheumatoid arthritis: an integrated analysis from clinical trials. Ann Rheum Dis. 2013. doi:10.1136/annrheumdis-2013-203660.

  32. Smolen JS, Braun J, Dougados M, et al. Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. Ann Rheum Dis. 2014;73(1):6–16.

    Article  PubMed Central  PubMed  Google Scholar 

  33. van der Heijde D, Sieper J, Maksymowych WP, et al. 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Ann Rheum Dis. 2011;70(6):905–8.

    Article  PubMed  Google Scholar 

  34. Braun J, van den Berg R, Baraliakos X, et al. 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis. 2011;70(6):896–904.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  35. Gossec L, Smolen JS, Gaujoux-Viala C, et al. European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis. 2012;71(1):4–12.

    Article  CAS  PubMed  Google Scholar 

  36. Ritchlin CT, Kavanaugh A, Gladman DD, et al. Treatment recommendations for psoriatic arthritis. Ann Rheum Dis. 2009;68(9):1387–94.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  37. Coates LC, Tillett W, Chandler D, et al. The 2012 BSR and BHPR guideline for the treatment of psoriatic arthritis with biologics. Rheumatology. 2013;52(10):1754–7.

    Article  PubMed  Google Scholar 

  38. European Medicines Agency. Humira (adalimumab): summary of product characteristics. 2013. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000481/WC500050870.pdf. Accessed 8 May 2014.

  39. Ruderman EM. Overview of safety of non-biologic and biologic DMARDs. Rheumatology. 2012;51(Suppl 6):vi37–43.

    Article  PubMed  Google Scholar 

  40. Nesbitt A, Fossati G, Bergin M, et al. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents. Inflamm Bowel Dis. 2007;13(11):1323–32.

    Article  PubMed  Google Scholar 

  41. Ueda N, Tsukamoto H, Mitoma H, et al. The cytotoxic effects of certolizumab pegol and golimumab mediated by transmembrane tumor necrosis factor alpha. Inflamm Bowel Dis. 2013;19(6):1224–31.

    Article  PubMed  Google Scholar 

  42. Heathfield SK, Parker B, Zeef LAH, et al. Certolizumab pegol attenuates the pro-inflammatory state in endothelial cells in a manner that is atheroprotective. Clin Exp Rheumatol. 2013;31(2):225–33.

    PubMed  Google Scholar 

  43. Palframan R, Airey M, Moore A, et al. Use of biofluorescence imaging to compare the distribution of certolizumab pegol, adalimumab, and infliximab in the inflamed paws of mice with collagen-induced arthritis. J Immunol Methods. 2009;348(1–2):36–41.

    Article  CAS  PubMed  Google Scholar 

Download references

Disclosure

The preparation of this review was not supported by any external funding. During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on this article. Changes resulting from comments received were made by the author on the basis of scientific and editorial merit. Sohita Dhillon is a salaried employee of Adis/Springer.

Author information

Authors and Affiliations

  1. Adis, Level 1, 5 The Warehouse Way, Northcote 0627; Private Bag 65901, Mairangi Bay, 0754, Auckland, New Zealand

    Sohita Dhillon

Authors
  1. Sohita Dhillon
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sohita Dhillon.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Dhillon, S. Certolizumab Pegol: A Review of Its Use in Patients with Axial Spondyloarthritis or Psoriatic Arthritis. Drugs 74, 999–1016 (2014). https://doi.org/10.1007/s40265-014-0239-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40265-014-0239-z

Keywords

Search

Navigation